# Zucara Therapeutics Inc.: Research, Toronto, Canada > Zucara Therapeutics Inc.: Zucara Therapeutics Inc. Based in Toronto, Canada. Founded 2015. What Millionrounds holds on them, and what we have not seen. Source: https://millionrounds.com/startup/zucara-therapeutics-inc (Millionrounds; every figure on the page links to its filing or article) Canada · [Research startup](https://millionrounds.com/companies) # Zucara Therapeutics Inc. Zucara Therapeutics Inc. Funding reported Last round: Series B Research Toronto, Canada Company summary - **Founded:** 2015 11 years old - **Team:** 13 11 to 50 people - **Funding reported:** 64.4M as listed, currency not stated - **Last round:** Series B Nov 2024 How sure we are - ✓ **Listed** We know it exists and what it does - 2 **Funding reported** A company dataset reports a raise - 3 **Observed** A filing or a dated announcement confirms a round No round for Zucara Therapeutics Inc. has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology) ## About Zucara Therapeutics Inc. Zucara Therapeutics Inc. is a biopharmaceutical company focused on developing ZT-01, a once-daily therapeutic aimed at preventing hypoglycemia in patients with diabetes, particularly those with Type 1 diabetes and insulin-dependent Type 2 diabetes. Founded in December 2014, Zucara operates from offices in Toronto, Ontario, and Vancouver, British Columbia. The company is currently in Phase 2 Clinical Studies for ZT-01, having secured funding following positive proof-of-concept data in 2022 and completing a US$25 million Series B financing in 2025. ZT-01 is a novel peptide therapy delivered via subcutaneous injection. It works by blocking somatostatin type 2 receptors in the pancreas, which helps restore glucagon secretion, the body's natural defense against low blood sugar. This preventative approach is designed for patients with a history of severe, recurrent hypoglycemia, addressing a significant need among the approximately 2 million patients worldwide with Type 1 diabetes at risk of such episodes. Zucara is also exploring additional peptide therapies for non-muscle invasive bladder cancer, expanding its focus beyond diabetes. ## What company datasets say Zucara Therapeutics Inc. raised Funding, as reported Reported in all **64.4M** in the source's currency Last round **Series B** Last round size **20M** Last round date **Nov 2024** Investors listed **5** ## On 7 portfolio pages Investors who name them - [T1D Fund](https://millionrounds.com/fund/t1d-fund) - [adMare Bio Innovations](https://millionrounds.com/fund/admare-bio-innovations) - [Xontogeny](https://millionrounds.com/fund/xontogeny) - [Novateur Ventures Inc.](https://millionrounds.com/fund/novateur-ventures-inc) - [Kapplex](https://millionrounds.com/fund/tiap-toronto-innovation-acceleration-partners) - [Centre for Drug Research and Development](https://millionrounds.com/fund/centre-for-drug-research-and-development) - [Toronto Innovation Acceleration Partners (TIAP)](https://millionrounds.com/fund/toronto-innovation-acceleration-partners-tiap) Each firm lists Zucara Therapeutics Inc. on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source. ## The company, in detail What they build Known for medical research funding health care biopharma innovation targeted hormone therapy biotechnology research insulin-dependent diabetes hypoglycemia management impact on diabetes care bladder tumor absorption drug development support peptide antagonists targeted peptide therapy hypoglycemia innovative therapy hospital & health care medical Built with from their website Contact Form 7 WordPress.org Viewport Meta The Events Calendar Priority Hints Google Font API Microsoft Exchange Genesis MySQL PrimeNG +8 more Microsoft 365 Apps & Services Mobile Friendly jQuery RSS Google Analytics Wordpress Microsoft Exchange Online Really Simple SSL & Security - **Sector:** Research - **Industry code:** NAICS 32541, 541714, SIC 2834, 8731 - **Region:** Ontario - **Revenue:** 6.5M a year, as listed ## Research in Canada Startups like it - [**Altis Labs** Toronto · founded 2019 *Raised*](https://millionrounds.com/company/altis-labs) - [**Sitka Biopharma** Vancouver · founded 2013 *Raised*](https://millionrounds.com/company/sitka-biopharma) - [**ServiceNow AI Research** Montreal · founded 2016](https://millionrounds.com/startup/servicenow-ai-research) - [**DalCor Pharmaceuticals** Montreal · founded 2015](https://millionrounds.com/startup/dalcor-pharmaceuticals) - [**Notch Therapeutics** Vancouver · founded 2018](https://millionrounds.com/startup/notch-therapeutics) - [**chemical.ai** Toronto · founded 2018](https://millionrounds.com/startup/chemical-ai) - [**Congruence Therapeutics** Montreal · founded 2021](https://millionrounds.com/startup/congruence-therapeutics) - [**Nomic Bio** Montreal · founded 2017](https://millionrounds.com/startup/nomic-bio) ## Is this your company? Add your raise, your deck and your story, and put Zucara Therapeutics Inc. in front of investors. Or tell us what we have wrong. [List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)